# US Parkinsons Disease Therapeutics Market > US Parkinson's Disease Therapeutics Market Research Report By Treatment Type (Medication, Surgical Therapy, Carbidopa/Levodopa Enteral Suspension) and By End User (Hospitals & Clinics, Academic & Industrial Research) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.34% - **2024:** $ 1,450 Million - **2025:** $ 1,570.93 Million - **2035:** $ 3,500 Million - **Key Players:** AbbVie (US), Boehringer Ingelheim (DE), Novartis (CH), Roche (CH), Teva Pharmaceutical Industries (IL), Amgen (US), Eli Lilly and Company (US), UCB (BE), Acorda Therapeutics (US) **Report ID:** MRFR/Pharma/16461-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** July 20, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-parkinsons-disease-therapeutics-market-17989 --- ## Market Summary **US Parkinson's Disease Therapeutics Market Overview** As per MRFR analysis, the US Parkinson's Disease Therapeutics Market Size was estimated at 1.24 (USD Billion) in 2023. The US Parkinson's Disease Therapeutics Market Industry is expected to grow from 1.5(USD Billion) in 2024 to 3.5 (USD Billion) by 2035. The US Parkinson's Disease Therapeutics Market CAGR (growth rate) is expected to be around 8.007% during the forecast period (2025 - 2035). **Key US Parkinson's Disease Therapeutics Market Trends Highlighted** The US Parkinson's Disease Therapeutics Market is experiencing notable trends driven by an aging population and increasing awareness of the disease. As the baby boomer generation ages, the prevalence of Parkinson's disease is expected to rise, leading to a greater demand for effective therapeutic options. Additionally, advancements in research and technology are fostering the development of innovative treatments, including disease-modifying therapies and neuroprotective strategies, creating hope for improved patient outcomes. Key market drivers encompass government initiatives and funding aimed at enhancing research and awareness regarding Parkinson's disease. The National Institutes of Health (NIH) and other organizations are significantly contributing to research efforts, aiming to unlock better treatment solutions and understanding of the disease. Furthermore, pharmaceutical companies are actively investing in pipeline candidates, focusing on both symptomatic relief and potential disease-modifying therapies, which are expected to transform patient care in the near future. Opportunities to be captured include the development of wearable technologies and digital health tools that cater to patient needs and improve treatment adherence.  As personalized medicine continues to gain traction, there is a significant opportunity for therapies tailored to individual genetic profiles and lifestyle factors.Additionally, the growing interest in collaborations among academic institutions, biotech firms, and pharmaceutical companies presents potential for accelerated research and the introduction of groundbreaking therapies to the market. Recent trends indicate a rise in clinical trials for novel therapies, which encourages innovation in treatment approaches. The increasing integration of telehealth services is also noteworthy, enabling better access to specialists for patients who may have mobility challenges. Overall, the evolving landscape of the US Parkinson's Disease Therapeutics Market highlights substantial growth potential shaped by these trends and market drivers. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **US Parkinson's Disease Therapeutics Market Drivers** Increase in Aging Population The United States is witnessing a significant increase in its aging population, which is a major driver for the US Parkinson's Disease Therapeutics Market Industry. According to data from the U.S. Census Bureau, the number of individuals aged 65 and older is projected to rise from approximately 54 million in 2020 to around 80 million by 2040. This demographic shift indicates a higher prevalence of Parkinson's disease, as the condition is primarily diagnosed in individuals over the age of 60. The American Parkinson Disease Association and similar organizations provide substantial resources and support for affected individuals, contributing to increased awareness and demand for effective therapeutics in the market. Moreover, with the growing incidence of age-related neurological disorders, the potential for new therapeutic developments presents a significant opportunity for market growth. Advancements in Research and Development The US [Parkinson's Disease Therapeutics Market](../../../reports/parkinsons-disease-therapeutics-market-1572) Industry is experiencing remarkable growth driven by advancements in Research and Development (R&D) in therapeutics and drug formulations. Increased funding for neurological research, particularly from institutions such as the National Institutes of Health (NIH), has led to breakthroughs in understanding the pathophysiology of Parkinson's disease. The NIH reported an increase in funding for Parkinson's disease research from $175 million in 2015 to nearly $300 million in 2022. This upward trend in investment is fostering innovation in drug development, resulting in more effective treatment options. Furthermore, collaborations between pharmaceutical companies and academic institutions enhance the development pipeline, ensuring a steady introduction of new therapies to the market. Growing Patient Awareness and Advocacy Awareness about Parkinson's disease and the importance of treatment options is increasing amongst patients and caregivers in the United States, significantly impacting the US Parkinson's Disease Therapeutics Market Industry. Organizations such as the Parkinson's Foundation and the Michael J. Fox Foundation are actively campaigning to inform the public about Parkinson's disease, its symptoms, and available treatments.  These advocacy efforts have increased understanding and recognition of the disease, resulting in more patients seeking medical advice and therapeutic options.According to recent surveys, about 92% of individuals diagnosed with Parkinson's disease are actively seeking information on treatment options, highlighting a growing demand for effective therapeutics to manage symptoms and improve quality of life. Investment in Innovative Therapeutics Significant investment in innovative therapeutic approaches for Parkinson's disease is becoming a prominent driver in the US Parkinson's Disease Therapeutics Market Industry. Biopharmaceutical companies are exploring novel therapies, including gene therapy, stem cell treatments, and advanced neuroprotective agents to revolutionize how Parkinson's is treated.  The Pharmaceutical Research and Manufacturers of America reported that in 2022, more than 60 potential new therapies targeting neurological disorders were in various stages of development within the U.S., with many focusing specifically on Parkinson's disease.This surge in innovation, combined with favorable regulatory environments encouraged by the U.S. Food and Drug Administration, elevates the potential for rapid market expansion as new, effective treatments are introduced. **US Parkinson's Disease Therapeutics Market Segment Insights:** **Parkinson's Disease Therapeutics Market Treatment Type Insights** The US Parkinson's Disease Therapeutics Market has seen significant advancements in recent years, particularly in the Treatment Type segment, which encompasses various approaches to managing the disease. This market is driven by an increasing prevalence of Parkinson's disease, with the growing aging population contributing as a major factor. Among the various treatment types, Medication stands out as a foundational element of therapy. It involves pharmacological agents designed to alleviate symptoms and improve the quality of life for patients. The rise of specific drug formulations enables tailored treatments that can address the unique needs of individual patients. On the other hand, Surgical Therapy represents a crucial alternative treatment option, primarily utilized for patients who do not respond adequately to medication. Procedures such as deep brain stimulation have gained traction, demonstrating efficacy in managing motor symptoms, proving to be a pivotal part of patient care for more advanced stages of the disease. This option has become increasingly significant as it allows patients to maintain a greater degree of independence and functionality, directly impacting their day-to-day lives. Moreover, Carbidopa/Levodopa Enteral Suspension is recognized as an innovative therapy that provides continuous dopaminergic stimulation. This delivery method helps to minimize peak-dose dyskinesias, offering more stable control of symptoms. It is particularly important as it represents a shift towards personalized medicine in the treatment of Parkinson's disease, responding to the specific needs of patients as their disease progresses. The combination of these treatments illustrates a multi-faceted approach to managing Parkinson's disease, addressing the complexity and variability of symptoms that patients experience.  Additionally, trends such as the increasing integration of technology in therapeutics and patient monitoring systems are likely to bolster treatment efficacy and improve patient outcomes. However, despite the promising advancements in Treatment Type, challenges such as high costs and access disparities remain hurdles that need to be addressed to ensure that all patients have equitable access to these critical therapies. As the US Parkinson's Disease Therapeutics Market continues to evolve, the emphasis on diverse and individualized treatment options will play a vital role in enhancing the care and quality of life for those living with Parkinson's disease. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Parkinson's Disease Therapeutics Market End User Insights** The US Parkinson's Disease Therapeutics Market is significantly shaped by its End User segment, which plays a crucial role in the delivery of care and research related to the disease. Hospitals and clinics are essential for the diagnosis and management of Parkinson's Disease, providing patients with specialized treatment options and access to healthcare professionals. This segment often drives patient engagement and advances therapeutic innovations through direct interactions with practitioners.  On the other hand, academic and industrial research institutions contribute to the development of new therapies and treatment strategies, focusing on understanding the disease's underlying mechanisms and exploring novel drug discoveries.These research facilities often collaborate with healthcare providers to translate findings into clinical settings, ensuring that therapeutic advancements reach patients effectively.  The synergy between these sub-segments enhances the overall landscape of the US Parkinson's Disease Therapeutics Market, fostering an environment where patient care and scientific discovery thrive. This integration of healthcare delivery and research initiatives represents a significant opportunity for growth and innovation in addressing the needs of individuals living with Parkinson's Disease. **US Parkinson's Disease Therapeutics Market Key Players and Competitive Insights:** The competitive landscape of the US Parkinson's Disease Therapeutics Market is characterized by a blend of established pharmaceutical companies and emerging biotech firms. This market is rapidly evolving, driven by an increasing prevalence of Parkinson's disease, ongoing research efforts, and advancements in therapeutic interventions.  Companies are focused on developing innovative treatments, including orally administered drugs, injectables, and future therapies targeting specific disease mechanisms. There is a strong emphasis on research and development strategies to enhance patient outcomes and address the unmet needs of Parkinson's disease management. Collaboration among stakeholders, including academic institutions and regulatory bodies, plays a crucial role in bringing effective therapies to market and navigating the complexities associated with Parkinson's disease treatment. Merck and Co is a prominent player in the US Parkinson's Disease Therapeutics Market, leveraging its extensive research capabilities and global presence to strengthen its market position. While its portfolio shows a commitment to neurological health, the company's focus on strategic partnerships and collaborations with academic institutions has amplified its innovative therapy development. Merck and Co’s robust clinical trial programs and investment in next-generation therapies showcase its dedication to addressing Parkinson's disease. The company's strengths lie in its well-established reputation, advanced manufacturing capabilities, and comprehensive distribution networks, allowing it to efficiently reach healthcare providers and patients across the United States. Such competitive advantages enable Merck and Co to maintain a significant role within a market striving for advancements in treatment approaches. Teva Pharmaceutical Industries has also carved a niche within the US Parkinson's Disease Therapeutics Market, mainly through a portfolio that includes key products designed to alleviate the symptoms of the disease and enhance the quality of life for patients. The company's presence in the market is underpinned by a range of generic treatments as well as branded therapies, which allows Teva to cater to various segments of the patient population.  Teva's strengths include its commitment to research and development that continually seeks innovative solutions, along with its operational efficiencies that contribute to cost-effective treatment options. Over the years, Teva has pursued strategic mergers and acquisitions to bolster its pipeline and expand its footprint in the neurology sector, further solidifying its competitive edge in the US market for Parkinson's disease therapeutics. This approach has not only enriched Teva's offering but also positioned it as a formidable competitor in an increasingly complex and competitive landscape. **Key Companies in the US Parkinson's Disease Therapeutics Market Include:** **US Parkinson's Disease Therapeutics Market Industry Developments** The US Parkinson's Disease Therapeutics Market has seen significant developments recently. In October 2023, neurodegenerative disease-focused companies like Neurocrine Biosciences and AbbVie continue to advance their products through clinical trials, enhancing patient care and treatment options. Additionally, in September 2023, Teva Pharmaceutical Industries announced progress in its research for novel formulations aimed at improving patient adherence and outcomes. Moreover, Merck and Co has invested heavily in Research and Development strategies targeting biomarker-driven therapy as a means to personalize treatment approaches.  In terms of mergers and acquisitions, Horizon Therapeutics established a collaboration with another pharmaceutical entity in August 2023 to expand its product portfolio related to Parkinson's therapy, showcasing an upward trend in consolidation efforts among major players. Companies like GlaxoSmithKline and Bristol Myers Squibb are also actively engaged in expanding their therapeutic formulations to cater to the growing demand. The overall market valuation for the Parkinson's Disease therapeutics has shown a steady increase, driven by innovation and a rising patient population within the U.S. over the past two years. ## **US Parkinson's Disease Therapeutics Market Segmentation Insights** ### **Parkinson's Disease Therapeutics Market Treatment Type****Outlook** ### **Parkinson's Disease Therapeutics Market End User****Outlook** ## Market Drivers ### Regulatory Support and Incentives Regulatory support and incentives play a pivotal role in shaping the parkinsons disease-therapeutics market. The US Food and Drug Administration (FDA) has implemented various programs aimed at expediting the development and approval of new therapies for Parkinson's disease. Initiatives such as the Breakthrough Therapy Designation and Fast Track designation are designed to facilitate quicker access to innovative treatments. In 2025, the number of therapies receiving expedited review has increased, reflecting the regulatory body's commitment to addressing unmet medical needs. This supportive regulatory environment is likely to encourage pharmaceutical companies to invest in research and development, ultimately enhancing the therapeutic options available in the market. ### Growing Investment in Biotechnology The growing investment in biotechnology is a significant driver for the parkinsons disease-therapeutics market. Venture capital funding and public-private partnerships are increasingly directed towards biopharmaceutical companies focused on developing novel therapies for [neurodegenerative diseases](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218). In 2025, the biotechnology sector has attracted over $5 billion in investments specifically for Parkinson's disease research, indicating a robust interest in innovative treatment solutions. This influx of capital is likely to accelerate the development of cutting-edge therapeutics, including gene therapies and biologics, which may offer new hope for patients. As investment continues to rise, the parkinsons disease-therapeutics market is expected to expand, providing a wider array of treatment options. ### Rising Awareness and Early Diagnosis Rising awareness about Parkinson's disease and its symptoms is significantly impacting the parkinsons disease-therapeutics market. Educational campaigns and advocacy efforts have led to increased recognition of the disease, facilitating earlier diagnosis and intervention. Early diagnosis is crucial, as it allows for timely therapeutic intervention, which can potentially slow disease progression. In 2025, it is estimated that early diagnosis initiatives have contributed to a 20% increase in diagnosed cases, leading to a corresponding rise in demand for therapeutics. This heightened awareness not only benefits patients but also encourages healthcare providers to prioritize treatment options, thereby stimulating market growth. ### Advancements in Research and Development Ongoing advancements in research and development are crucial for the evolution of the parkinsons disease-therapeutics market. Increased funding from both public and private sectors has led to a surge in clinical trials and innovative treatment modalities. For instance, the National Institutes of Health (NIH) has allocated substantial resources towards understanding the pathophysiology of Parkinson's disease, which has resulted in the identification of new therapeutic targets. In 2025, the market is witnessing a notable increase in the number of investigational drugs, with over 50 compounds currently in various stages of clinical trials. This influx of research is likely to enhance the therapeutic landscape, offering hope for improved patient outcomes and driving market expansion. ### Aging Population and Increased Incidence The aging population in the US is a significant driver for the parkinsons disease-therapeutics market. As individuals age, the risk of developing neurodegenerative disorders, including Parkinson's disease, escalates. Current estimates suggest that approximately 1 million people in the US are living with Parkinson's disease, a figure that is projected to rise as the population ages. This demographic shift is likely to increase the demand for effective therapeutics, thereby propelling market growth. Furthermore, the prevalence of Parkinson's disease is expected to double by 2040, indicating a pressing need for innovative treatment options. The parkinsons disease-therapeutics market must adapt to this growing patient population, focusing on developing therapies that cater to the unique needs of older adults. ## Future Outlook The Parkinson's disease-therapeutics market is projected to grow at an 8.34% CAGR from 2025 to 2035, driven by advancements in drug development and increasing patient awareness. **New opportunities:** - Development of personalized medicine approaches for tailored treatment plans. - Expansion of telehealth services for remote patient monitoring and consultations. - Investment in AI-driven drug discovery platforms to accelerate therapeutic development. By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased demand. ## Segment Insights ### By Treatment Type: Medication (Largest) vs. Surgical Therapy (Fastest-Growing) The US parkinsons disease-therapeutics market showcases a diverse array of treatment types, with Medication leading in market share, reflecting its established role in patient management. Surgical Therapy, although smaller in comparison, is gaining traction due to advancements in technology and techniques that enhance patient outcomes, capturing an increasing segment of the market. Growth trends indicate a shift towards innovative treatments. The demand for Medication is driven by ongoing research and development, leading to new formulations and applications. In contrast, Surgical Therapy is seeing rapid adoption as awareness grows and clinical evidence supporting its efficacy accumulates, positioning it as a preferred option for patients with advanced conditions. Medication (Dominant) vs. Surgical Therapy (Emerging) Medication remains the dominant player in the US parkinsons disease-therapeutics market, characterized by a wide range of options, including dopamine agonists and MAO-B inhibitors. The established nature of these therapeutic modalities ensures strong physician and patient acceptance. Conversely, Surgical Therapy represents an emerging alternative, particularly appealing for patients who do not respond adequately to medication. Techniques such as deep brain stimulation are becoming more refined, offering hope for improved quality of life. Both segments are integral to the overall treatment landscape, with Medication maintaining its leading status while Surgical Therapy's innovative approaches promise rapid growth and increased adoption among healthcare professionals. ### By End-User: Hospitals & Clinics (Largest) vs. Academic & Industrial Research (Fastest-Growing) In the US parkinsons disease-therapeutics market, Hospitals & Clinics represent the largest end-user segment, attributed to their pivotal role in patient diagnosis, treatment, and ongoing care. This segment holds a significant market share due to the high number of Parkinson's disease patients relying on these healthcare facilities for comprehensive treatment options and access to therapeutic innovations. Conversely, Academic & Industrial Research is emerging as the fastest-growing segment, driven by the surge in research initiatives focused on Parkinson's disease. Increased funding for neurological studies and the collaboration between academia and pharmaceutical companies are propelling this segment's growth. This trend is expected to continue as new therapeutic solutions are developed, enhancing our understanding and management of Parkinson's disease. Hospitals & Clinics (Dominant) vs. Academic & Industrial Research (Emerging) Hospitals & Clinics stand as the dominant force in the US parkinsons disease-therapeutics market, largely due to their established infrastructure and access to specialized care, ensuring a robust therapeutic approach for patients. These facilities not only provide treatment but also engage in [clinical trials](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787), contributing to the development of new therapies. In contrast, the Academic & Industrial Research segment is rapidly emerging as key players in the therapeutic landscape. Their focus on pioneering research, combined with collaborations with pharmaceutical companies, allows them to innovate and create new therapeutic options. This segment is vital for the continuous evolution of treatment modalities, pushing the boundaries of traditional therapies and enhancing patient outcomes. ## Competitive Benchmarking The parkinsons disease-therapeutics market is characterized by a dynamic competitive landscape, driven by a confluence of innovation, strategic partnerships, and a growing emphasis on patient-centric solutions. Major players such as AbbVie (US), Novartis (CH), and Eli Lilly and Company (US) are actively shaping the market through their distinct operational focuses. AbbVie (US) has been particularly aggressive in its research and development efforts, aiming to enhance its portfolio with novel therapies that address unmet medical needs. Meanwhile, Novartis (CH) appears to be leveraging its global reach to expand access to its treatments, while Eli Lilly and Company (US) is increasingly focusing on digital health solutions to improve patient engagement and adherence, collectively fostering a competitive environment that prioritizes innovation and patient outcomes.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market is moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of therapeutic options, yet it also necessitates that companies differentiate themselves through unique value propositions and operational excellence. In October AbbVie (US) announced a strategic collaboration with a leading biotechnology firm to co-develop a novel gene therapy aimed at slowing the progression of Parkinson's disease. This partnership is expected to leverage advanced gene-editing technologies, potentially positioning AbbVie at the forefront of innovative treatment modalities. The strategic importance of this collaboration lies in its potential to address the underlying causes of the disease, thereby enhancing AbbVie's competitive edge in a market that increasingly values breakthrough therapies. In September Novartis (CH) launched a new digital platform designed to facilitate remote monitoring of Parkinson's disease patients. This initiative not only aligns with the growing trend of telehealth but also underscores Novartis's commitment to integrating technology into patient care. By enabling real-time data collection and analysis, the platform may significantly improve treatment outcomes and patient satisfaction, thereby reinforcing Novartis's market position. In August Eli Lilly and Company (US) expanded its partnership with a tech startup specializing in artificial intelligence to enhance drug discovery processes. This collaboration aims to streamline the identification of potential therapeutic candidates, thereby accelerating the development timeline for new treatments. The strategic significance of this move is profound, as it positions Eli Lilly to capitalize on AI advancements, potentially leading to more effective therapies and a stronger foothold in the competitive landscape. As of November current trends in the parkinsons disease-therapeutics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are playing a pivotal role in shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it is likely that competitive differentiation will evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution suggests that companies that prioritize these elements will be better positioned to thrive in an increasingly complex and competitive market. ## Recent News & Developments The US Parkinson's Disease Therapeutics Market has seen significant developments recently. In October 2023, neurodegenerative disease-focused companies like Neurocrine Biosciences and AbbVie continue to advance their products through clinical trials, enhancing patient care and treatment options. Additionally, in September 2023, Teva Pharmaceutical Industries announced progress in its research for novel formulations aimed at improving patient adherence and outcomes. Moreover, Merck and Co has invested heavily in Research and Development strategies targeting biomarker-driven therapy as a means to personalize treatment approaches.  In terms of mergers and acquisitions, Horizon Therapeutics established a collaboration with another pharmaceutical entity in August 2023 to expand its product portfolio related to Parkinson's therapy, showcasing an upward trend in consolidation efforts among major players. Companies like GlaxoSmithKline and Bristol Myers Squibb are also actively engaged in expanding their therapeutic formulations to cater to the growing demand. The overall market valuation for the Parkinson's Disease therapeutics has shown a steady increase, driven by innovation and a rising patient population within the U.S. over the past two years. ## Report Scope | MARKET SIZE 2024 | 1450.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1570.93(USD Million) | | MARKET SIZE 2035 | 3500.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.34% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie (US), Boehringer Ingelheim (DE), Novartis (CH), Roche (CH), Teva Pharmaceutical Industries (IL), Amgen (US), Eli Lilly and Company (US), UCB (BE), Acorda Therapeutics (US) | | Segments Covered | Treatment Type, End-User | | Key Market Opportunities | Advancements in personalized medicine and digital therapeutics enhance treatment options in the parkinsons disease-therapeutics market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Parkinson's disease therapeutics market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US parkinsons disease-therapeutics market in 2024?** A: The market valuation was $1450.0 Million in 2024. **Q: What is the projected market valuation for the US parkinsons disease-therapeutics market in 2035?** A: The projected valuation for 2035 is $3500.0 Million. **Q: What is the expected CAGR for the US parkinsons disease-therapeutics market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 8.34%. **Q: Which treatment type segment had the highest valuation in the US parkinsons disease-therapeutics market?** A: The Medication segment had the highest valuation, ranging from $800.0 Million to $1800.0 Million. **Q: What is the valuation range for Surgical Therapy in the US parkinsons disease-therapeutics market?** A: The valuation range for Surgical Therapy is between $300.0 Million and $700.0 Million. **Q: How much is the Carbidopa/Levodopa Enteral Suspension segment valued at?** A: The Carbidopa/Levodopa Enteral Suspension segment is valued between $350.0 Million and $1000.0 Million. **Q: What are the key end-user segments in the US parkinsons disease-therapeutics market?** A: The key end-user segments include Hospitals & Clinics and Academic & Industrial Research. **Q: What is the valuation range for Hospitals & Clinics in the US parkinsons disease-therapeutics market?** A: The valuation range for Hospitals & Clinics is from $800.0 Million to $1800.0 Million. **Q: What is the valuation range for Academic & Industrial Research in the US parkinsons disease-therapeutics market?** A: The valuation range for Academic & Industrial Research is between $650.0 Million and $1700.0 Million. **Q: Who are the key players in the US parkinsons disease-therapeutics market?** A: Key players include AbbVie, Boehringer Ingelheim, Novartis, Roche, Teva Pharmaceutical Industries, Amgen, Eli Lilly and Company, UCB, and Acorda Therapeutics. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-parkinsons-disease-therapeutics-market-17989*